tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

VRDN Stock Latest News

Viridian Therapeutics announces inducement grant under Nasdaq listing rule
The FlyViridian Therapeutics announces inducement grant under Nasdaq listing rule
6d ago
VRDN
Viridian Therapeutics Stockholders Approve Key Proposals
PremiumCompany Announcements
Viridian Therapeutics Stockholders Approve Key Proposals
15d ago
8K
VRDN
Viridian Therapeutics’ Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
PremiumRatings
Viridian Therapeutics’ Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
2M ago
VRDN
Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
2M ago
VRDN
Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects
PremiumRatings
Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects
2M ago
VRDN
Viridian Therapeutics: Promising Data and Market Position Justify Buy Rating
PremiumRatingsViridian Therapeutics: Promising Data and Market Position Justify Buy Rating
2M ago
VRDN
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans
Premium
Ratings
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans
2M ago
VRDN
Promising Long-Term Data and Strategic Advancements Position Viridian Therapeutics for Growth
Premium
Ratings
Promising Long-Term Data and Strategic Advancements Position Viridian Therapeutics for Growth
2M ago
VRDN
Viridian Reports Positive Phase 3 Trial Results
PremiumCompany Announcements
Viridian Reports Positive Phase 3 Trial Results
2M ago
8K
VRDN
Viridian Therapeutics announces long-term durability data from THRIVE trial
PremiumThe Fly
Viridian Therapeutics announces long-term durability data from THRIVE trial
2M ago
VRDN
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
2M ago
VRDN
Viridian Therapeutics receives FDA breakthrough designation for Veligrotug
PremiumThe Fly
Viridian Therapeutics receives FDA breakthrough designation for Veligrotug
2M ago
VRDN
Viridian Therapeutics price target lowered to $19 from $22 at B. Riley
PremiumThe FlyViridian Therapeutics price target lowered to $19 from $22 at B. Riley
2M ago
VRDN
Viridian Therapeutics: Strategic Developments and Strong Financial Position Justify Buy Rating
Premium
Ratings
Viridian Therapeutics: Strategic Developments and Strong Financial Position Justify Buy Rating
2M ago
VRDN
Viridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data
Premium
Ratings
Viridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data
2M ago
VRDN
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP
PremiumThe Fly
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP
2M ago
VRDN
Viridian Therapeutics Reports Q1 2025 Progress and Financials
PremiumCompany Announcements
Viridian Therapeutics Reports Q1 2025 Progress and Financials
2M ago
VRDN
Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating
2M ago
VRDN
Buy Rating for Viridian Therapeutics: Strong Pipeline and Financial Position Drive Strategic Advancements
PremiumRatings
Buy Rating for Viridian Therapeutics: Strong Pipeline and Financial Position Drive Strategic Advancements
2M ago
VRDN
Viridian Therapeutics: Promising Outlook with Strong Pipeline and Regulatory Progress
PremiumRatingsViridian Therapeutics: Promising Outlook with Strong Pipeline and Regulatory Progress
2M ago
VRDN
Viridian Therapeutics, Inc. (VRDN) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Viridian Therapeutics, Inc. (VRDN) Q1 Earnings Cheat Sheet
2M ago
VRDN
Buy Rating for Viridian Therapeutics Driven by Promising Pipeline and Strategic Positioning in Thyroid Eye Disease Market
Premium
Ratings
Buy Rating for Viridian Therapeutics Driven by Promising Pipeline and Strategic Positioning in Thyroid Eye Disease Market
3M ago
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >